PMID- 3133944
OWN - NLM
STAT- MEDLINE
DCOM- 19880805
LR  - 20131121
IS  - 0277-3732 (Print)
IS  - 0277-3732 (Linking)
VI  - 11 Suppl 1
DP  - 1988
TI  - Efficacy of buserelin in advanced prostate cancer and comparison with historical 
      controls.
PG  - S29-32
AB  - Buserelin (B) is a synthetic nonapeptide analogue of native LHRH. Upon continued 
      administration it reliably lowers the serum testosterone level to less than 100 
      ng/dl. It has been used in a clinical trial for the treatment of patients with 
      stage C, D1, and D2 prostate cancer. Analysis of efficacy of testosterone 
      suppression and toxicity included all 207 buserelin-treated patients. A 
      comparison with historical controls from two National Prostate Cancer Project 
      (NPCP) studies considered only the 147 evaluable patients with distant metastases 
      (stage D2). All patients received buserelin, 500 micrograms q 8 hours 
      subcutaneously (s.c.) for the first 7 days and then elected to take 200 
      micrograms s.c. daily or 400 micrograms q 8 hours by the intranasal (i.n.) route. 
      Seventy-three percent elected s.c. administration. Only 2% changed the route of 
      administration. The serum testosterone (T) level increased during week 1 in both 
      the s.c. (426 ng/dl) and the i.n. (521 ng/dl) group but reached castrate (less 
      than 100 mg/dl) levels by 4 weeks in 90% of patients. Subsequently, the 
      likelihood of having a T level greater than 100 was higher for those treated by 
      the i.n. than the s.c. route. The mean T level 4 and 12 months after therapy for 
      the s.c. treated patients was 29 and 28. These values were 61 and 53 for those 
      taking i.n. buserelin. This difference may in part be due to poor compliance. 
      Toxicity was minor. Twelve percent of 151 s.c. treated patients had at least one 
      episode of reaction at the injection site. None required discontinuation of the 
      agent. Seventy-two percent experienced hot flushes; this was the same for both 
      the s.c. and i.n. groups. Only 2 of 207 patients had a severe exacerbation of 
      symptoms (spinal cord compression) during the first week of therapy. The criteria 
      for response to therapy were those of the NPCP. There was no significant 
      difference in the percentage of patients achieving a response when comparing the 
      B-treated D2 patients to the NPCP D2 patients treated with DES, 3 mg daily, or 
      orchiectomy. More of the B-treated patients entered with pain, a poor performance 
      status, and weight loss than the DES/orchiectomy group. Nonetheless, the 
      progression-free survival did not differ among the treatments. In summary, 
      buserelin reliably lowers the serum T level by week 4 in 95% of men. Treatment 
      efficacy is equivalent to a historical group treated with either DES or 
      orchiectomy.
FAU - Soloway, M S
AU  - Soloway MS
AD  - Department of Urology, University of Tennessee, Memphis 38163.
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Am J Clin Oncol
JT  - American journal of clinical oncology
JID - 8207754
RN  - 731DCA35BT (Diethylstilbestrol)
RN  - PXW8U3YXDV (Buserelin)
SB  - IM
MH  - Buserelin/administration & dosage/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Diethylstilbestrol/therapeutic use
MH  - Humans
MH  - Male
MH  - Orchiectomy
MH  - Prognosis
MH  - Prostatic Neoplasms/*drug therapy/mortality
MH  - Time Factors
EDAT- 1988/01/01 00:00
MHDA- 1988/01/01 00:01
CRDT- 1988/01/01 00:00
PHST- 1988/01/01 00:00 [pubmed]
PHST- 1988/01/01 00:01 [medline]
PHST- 1988/01/01 00:00 [entrez]
PST - ppublish
SO  - Am J Clin Oncol. 1988;11 Suppl 1:S29-32.